The estimated Net Worth of Vincent R Anicetti is at least $3.33 Milion dollars as of 5 March 2021. Mr. Anicetti owns over 26,649 units of Coherus Biosciences Inc stock worth over $71,025 and over the last 7 years he sold CHRS stock worth over $1,446,330. In addition, he makes $1,810,840 as Chief Operating Officer at Coherus Biosciences Inc.
Vincent has made over 22 trades of the Coherus Biosciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 26,649 units of CHRS stock worth $411,994 on 5 March 2021.
The largest trade he's ever made was exercising 98,756 units of Coherus Biosciences Inc stock on 3 December 2020 worth over $1,614,661. On average, Vincent trades about 8,114 units every 20 days since 2018. As of 5 March 2021 he still owns at least 53,402 units of Coherus Biosciences Inc stock.
You can see the complete history of Mr. Anicetti stock trades at the bottom of the page.
Vincent R. Anicetti serves as Chief Operating Officer of the Company. He has served as our Chief Operating Officer since May 2018, served as our Chief, Quality and Compliance Officer from March 2018 to May 2018 and served as our Executive Vice President of Quality and Compliance from June 2014 to March 2018. Mr. Anicetti previously served as Executive Director of Quality of Boehringer Ingelheim, a pharmaceutical company, from February 2013 to May 2014. Prior to that, from June 2006 to September 2011, Mr. Anicetti served as Vice President of Biologics Quality at Genentech, a biotechnology corporation. Prior to that, Mr. Anicetti served as Vice President of Portfolio Management and Senior Director of Regulatory Affairs at Genentech. Since August 2011, Mr. Anicetti is also an Industry Professor at the Keck Graduate Institute, a private graduate school. Mr. Anicetti has a M.S. in Biological Sciences from San Francisco State University and currently serves on the board of directors of the San Francisco State University Foundation in San Francisco, California. 24
As the Chief Operating Officer of Coherus Biosciences Inc, the total compensation of Vincent Anicetti at Coherus Biosciences Inc is $1,810,840. There are 3 executives at Coherus Biosciences Inc getting paid more, with Dennis Lanfear having the highest compensation of $5,361,710.
Vincent Anicetti is 65, he's been the Chief Operating Officer of Coherus Biosciences Inc since 2018. There are 5 older and 10 younger executives at Coherus Biosciences Inc. The oldest executive at Coherus Biosciences Inc is Dr. Barbara K. Finck M.D., 74, who is the Acting Chief Medical Officer.
Vincent's mailing address filed with the SEC is COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Over the last 10 years, insiders at Coherus Biosciences Inc have traded over $94,360,509 worth of Coherus Biosciences Inc stock and bought 594,589 units worth $8,026,656 . The most active insiders traders include Llc Fmr, August J. Troendle oraz James Healy. On average, Coherus Biosciences Inc executives and independent directors trade stock every 26 days with the average trade being worth of $64,928. The most recent stock trade was executed by Mats Wahlstrom on 1 February 2024, trading 59,988 units of CHRS stock currently worth $100,180.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
Coherus Biosciences Inc executives and other stock owners filed with the SEC include: